{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:22:44Z","timestamp":1773523364361,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: To report a case of bilateral sterile intraocular inflammation following intravitreal aflibercept 8 mg (Eylea HD) injections. Case Presentation: An 89-year-old woman with bilateral neovascular age-related macular degeneration (nAMD) developed blurred vision and mild ocular pain in both eyes four days after receiving aflibercept 8 mg injections in both of her eyes. Examination revealed a marked anterior chamber reaction with Descemet\u2019s folds, 2+ vitreous cells, and 3+ vitreous haze bilaterally. Intraocular pressures were normal, and B-scan ultrasonography confirmed attached retinas with bilateral vitreous opacities. The clinical presentation initially raised concern for infectious endophthalmitis; however, the bilateral presentation, quiet conjunctivae, and prior history of sterile inflammation after aflibercept 2 mg supported a diagnosis of sterile intraocular inflammation. The patient was hospitalized and treated with intensive topical corticosteroids, antibiotics, and cycloplegics, resulting in rapid improvement and complete resolution of symptoms within four days with recovery of baseline vision. Conclusions: Intravitreal aflibercept 8 mg can be associated with bilateral sterile intraocular inflammation, even in patients who previously tolerated standard-dose aflibercept. Awareness of this potential adverse event is essential to avoid unnecessary interventions and to guide appropriate management.<\/jats:p>","DOI":"10.3390\/reports8040249","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:26:57Z","timestamp":1764318417000},"page":"249","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bilateral Sterile Intraocular Inflammation Following Intravitreal Aflibercept 8 mg Injections: A Case Report"],"prefix":"10.3390","volume":"8","author":[{"given":"Ram","family":"Cohen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Tel Aviv 64239, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8032-0111","authenticated-orcid":false,"given":"Tomer","family":"Kerman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Tel Aviv 64239, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-6238","authenticated-orcid":false,"given":"Omer","family":"Trivizki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Tel Aviv 64239, Israel"},{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: Optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12325-019-01147-6","article-title":"Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies","volume":"37","author":"Carrasco","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/09286586.2015.1122067","article-title":"Intraocular Inflammation Following Intravitreal Injection of Anti-VEGF Medications for Neovascular Age-Related Macular Degeneration","volume":"23","author":"Knickelbein","year":"2016","journal-title":"Ophthalmic Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ajo.2015.07.003","article-title":"Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome","volume":"160","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","article-title":"Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration","volume":"68","author":"Matsumoto","year":"2024","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12886-024-03827-6","article-title":"Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: A case report","volume":"25","author":"Hashiya","year":"2025","journal-title":"BMC Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hoffmann, L., Michels, S., Eandi, C., Karam, M.A., Figueiredo, E.C.d.O., and Hatz, K. (2024). Aflibercept high-dose (8mg) related intraocular inflammation (IOI)\u2014A case series. BMC Ophthalmol., 24.","DOI":"10.1186\/s12886-024-03788-w"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","article-title":"Noninfectious Intraocular Inflammation After Intravitreal Aflibercept","volume":"143","author":"Binder","year":"2025","journal-title":"JAMA Ophthalmol."},{"key":"ref_13","first-page":"e86113","article-title":"Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report","volume":"17","author":"Sato","year":"2025","journal-title":"Cureus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40942-025-00665-6","article-title":"Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Na\u00efve neovascular AMD: AI-assisted fluid volume analysis","volume":"11","author":"Cattaneo","year":"2025","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sisk, R.A. (2025). Occlusive Retinal Vasculitis After Aflibercept 8mg Injection for Wet Macular Degeneration. Retin. Cases Brief Rep.","DOI":"10.1097\/ICB.0000000000001757"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40662-024-00416-y","article-title":"Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: A case report and review of literature","volume":"11","author":"Lee","year":"2024","journal-title":"Eye Vis."},{"key":"ref_17","first-page":"24741264251330339","article-title":"Bilateral Sterile Granulomatous Uveitis Caused by Intravitreal Injections of Faricimab","volume":"9","author":"Hill","year":"2025","journal-title":"J. Vitr. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/24741264251358623","article-title":"Intraocular Inflammation Following Intravitreal Faricimab: Insights from Five Bilateral Cases","volume":"9","author":"Dhillon","year":"2025","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/eye.2009.143","article-title":"Bilateral intraocular inflammation after intravitreal bevacizumab in Behcet\u2019s disease","volume":"24","author":"Bae","year":"2010","journal-title":"Eye"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/ICB.0000000000001158","article-title":"Catastrophic, Bilateral Retinal Vascular Occlusion After Intravitreal Bevacizumab Injection","volume":"17","author":"Ng","year":"2023","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4274\/tjo.galenos.2020.84042","article-title":"Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection","volume":"51","author":"Kaya","year":"2021","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","article-title":"Postmarketing analysis of aflibercept-related sterile intraocular inflammation","volume":"133","author":"Hahn","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.oret.2019.04.006","article-title":"Aflibercept-Related Sterile Intraocular Inflammation Outcomes","volume":"3","author":"Greenberg","year":"2019","journal-title":"Ophthalmol. Retin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/IAE.0000000000000801","article-title":"Noninfectious vitritis after intravitreal injection of anti-VEGF agents: Variations in Rates and Presentation by Medication","volume":"36","author":"Williams","year":"2016","journal-title":"Retina"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: A narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.curtheres.2024.100742","article-title":"Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs","volume":"100","author":"Kim","year":"2024","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1167\/iovs.13-11821","article-title":"Fc\u03b3 receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration","volume":"55","author":"Murinello","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.xphs.2019.02.002","article-title":"An Assessment of the Ability of Submicron- and Micron-Size Silicone Oil Droplets in Dropped Prefillable Syringes to Invoke Early- and Late-Stage Immune Responses","volume":"108","author":"Krayukhina","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bjophthalmol-2019-313823","article-title":"Release of silicone oil and the off-label use of syringes in ophthalmology","volume":"104","author":"Melo","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/249\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:28:38Z","timestamp":1765877318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["reports8040249"],"URL":"https:\/\/doi.org\/10.3390\/reports8040249","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}